Attached files

file filename
EX-99.2 - EX-99.2 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC.pacb-20170202xex99_2.htm
EX-5.1 - EX-5.1 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC.pacb-20170202xex5_1.htm
8-K - 8-K - PACIFIC BIOSCIENCES OF CALIFORNIA, INC.pacb-20170202x8k.htm

Exhibit 99.1

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.



Consolidated Balance Sheets

(unaudited)













 

 

 

 

 



 

 

 

 

 



December 31,

(in thousands, except per share amounts)

2016

 

2015

Assets

 

 

 

 

 

Current assets

 

 

 

 

 

Cash and cash equivalents

$

16,765 

 

$

33,629 

Investments

 

55,213 

 

 

48,641 

Accounts receivable

 

11,421 

 

 

5,245 

Inventory

 

15,634 

 

 

10,955 

Prepaid expenses and other current assets

 

9,978 

 

 

12,071 

Total current assets

 

109,011 

 

 

110,541 

Property and equipment, net

 

14,560 

 

 

8,548 

Long-term restricted cash

 

4,500 

 

 

4,500 

Other long-term assets

 

9,813 

 

 

7,518 

Total assets

$

137,884 

 

$

131,107 

Liabilities and Stockholders’ Equity

 

 

 

 

 

Current liabilities

 

 

 

 

 

Accounts payable

$

8,359 

 

$

4,749 

Accrued expenses

 

16,604 

 

 

15,551 

Deferred service revenue, current

 

7,130 

 

 

6,815 

Deferred contractual revenue, current

 

 —

 

 

10,822 

Other liabilities, current

 

1,681 

 

 

241 

Total current liabilities

 

33,774 

 

 

38,178 

Deferred service revenue, non-current

 

1,297 

 

 

1,143 

Deferred contractual revenue, non-current

 

 —

 

 

1,312 

Other liabilities, non-current

 

1,683 

 

 

1,386 

Notes payable

 

16,106 

 

 

14,948 

Financing derivative

 

356 

 

 

600 

Total liabilities

 

53,216 

 

 

57,567 



 

 

 

 

 

Commitments and contingencies

 

 

 

 

 



 

 

 

 

 

Stockholders’ equity

 

 

 

 

 

Preferred Stock, $0.001 par value:

 

 

 

 

 

Authorized 50,000 shares; No shares issued or outstanding

 

 —

 

 

 —

Common Stock, $0.001 par value:

 

 

 

 

 

Authorized 1,000,000 shares; Issued and outstanding 92,677 and 79,983 shares at December 31, 2016 and 2015, respectively

 

93 

 

 

80 

Additional paid-in-capital

 

872,114 

 

 

786,636 

Accumulated other comprehensive income (loss)

 

 

 

(7)

Accumulated deficit

 

(787,544)

 

 

(713,169)

Total stockholders’ equity

 

84,668 

 

 

73,540 

Total liabilities and stockholders’ equity

$

137,884 

 

$

131,107 








 

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.



Consolidated Statements of Operations and Comprehensive Loss

(unaudited)













 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 



Years ended December 31,

(in thousands, except per share amounts)

2016

 

2015

 

2014

Revenue:

 

 

 

 

 

 

 

 

Product revenue

$

64,609 

 

$

37,502 

 

$

35,299 

Service and other revenue

 

13,971 

 

 

10,896 

 

 

8,511 

Contractual revenue

 

12,134 

 

 

44,384 

 

 

16,784 

Total revenue

 

90,714 

 

 

92,782 

 

 

60,594 

Cost of Revenue:

 

 

 

 

 

 

 

 

Cost of product revenue

 

34,512 

 

 

30,704 

 

 

29,626 

Cost of service and other revenue

 

12,042 

 

 

8,628 

 

 

7,566 

Total cost of revenue

 

46,554 

 

 

39,332 

 

 

37,192 

Gross profit

 

44,160 

 

 

53,450 

 

 

23,402 

Operating Expense:

 

 

 

 

 

 

 

 

Research and development

 

67,617 

 

 

60,440 

 

 

48,230 

Sales, general and administrative

 

47,787 

 

 

45,187 

 

 

38,026 

Gain on lease amendments

 

 —

 

 

(23,043)

 

 

 —

Total operating expense

 

115,404 

 

 

82,584 

 

 

86,256 

Operating loss

 

(71,244)

 

 

(29,134)

 

 

(62,854)

Interest expense

 

(3,234)

 

 

(2,926)

 

 

(2,828)

Other income (expense), net

 

103 

 

 

364 

 

 

(478)

Net loss

 

(74,375)

 

 

(31,696)

 

 

(66,160)

Other comprehensive loss:

 

 

 

 

 

 

 

 

Unrealized gain (loss) on investments

 

12 

 

 

(16)

 

 

(5)

Comprehensive loss

$

(74,363)

 

$

(31,712)

 

$

(66,165)

Net loss per share:

 

 

 

 

 

 

 

 

Basic and diluted net loss per share

$

(0.83)

 

$

(0.42)

 

$

(0.94)

Shares used in computing basic and diluted net loss per share

 

89,148 

 

 

75,614 

 

 

70,475 














 

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.



Consolidated Statements of Cash Flows

(unaudited)











 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 



Years Ended December 31,

(in thousands)

2016

 

2015

 

2014

Cash flows from operating activities

 

 

 

 

 

 

 

 

Net loss

$

(74,375)

 

$

(31,696)

 

$

(66,160)

Adjustments to reconcile net loss to net cash used in operating activities

 

 

 

 

 

 

 

 

Depreciation and amortization

 

3,875 

 

 

3,677 

 

 

4,221 

Amortization of debt discount and financing costs

 

1,158 

 

 

957 

 

 

793 

Stock-based compensation

 

19,562 

 

 

13,840 

 

 

9,943 

Non-cash portion of gain on lease amendments

 

 —

 

 

(3,043)

 

 

 —

Other items

 

(147)

 

 

(230)

 

 

507 

Changes in assets and liabilities

 

 

 

 

 

 

 

 

Accounts receivable

 

(6,176)

 

 

(1,738)

 

 

(660)

Inventory

 

(6,151)

 

 

(2,466)

 

 

(1,285)

Prepaid expenses and other assets

 

(202)

 

 

(17,889)

 

 

(224)

Accounts payable

 

3,402 

 

 

(716)

 

 

3,891 

Accrued expenses 

 

1,053 

 

 

5,732 

 

 

3,536 

Deferred service revenue

 

469 

 

 

708 

 

 

2,686 

Deferred contractual revenue

 

(12,134)

 

 

(14,386)

 

 

(6,784)

Other liabilities

 

1,737 

 

 

(639)

 

 

(1,932)

Net cash used in operating activities

 

(67,929)

 

 

(47,889)

 

 

(51,468)

Cash flows from investing activities

 

 

 

 

 

 

 

 

Purchase of property and equipment

 

(8,207)

 

 

(3,009)

 

 

(1,609)

Proceeds from disposal of property and equipment

 

10 

 

 

36 

 

 

 —

Long-term restricted cash 

 

 —

 

 

(4,500)

 

 

 —

Purchase of investments

 

(95,848)

 

 

(84,579)

 

 

(126,413)

Sales of investments

 

23,285 

 

 

8,317 

 

 

 —

Maturities of investments

 

65,896 

 

 

92,341 

 

 

147,586 

Net cash provided by (used in) investing activities

 

(14,864)

 

 

8,606 

 

 

19,564 

Cash flows from financing activities

 

 

 

 

 

 

 

 

Proceeds from issuance of common stock from equity plans

 

7,729 

 

 

7,363 

 

 

3,968 

Proceeds from issuance of common stock from "at-the-market" offering, net of issuance costs

 

58,200 

 

 

29,100 

 

 

38,023 

Net cash provided by financing activities

 

65,929 

 

 

36,463 

 

 

41,991 

Net increase (decrease) in cash and cash equivalents

 

(16,864)

 

 

(2,820)

 

 

10,087 

Cash and cash equivalents at beginning of period

 

33,629 

 

 

36,449 

 

 

26,362 

Cash and cash equivalents at end of period

$

16,765 

 

$

33,629 

 

$

36,449 



 

 

 

 

 

 

 

 

Supplemental disclosure of cash flow information

 

 

 

 

 

 

 

 

Interest paid

$

1,799 

 

$

1,794 

 

$

1,794 



 

 

 

 

 

 

 

 

Supplemental disclosure of non-cash investing and financing activities

 

 

 

 

 

 

 

 

Inventory transferred to property and equipment

 

1,282 

 

 

2,846 

 

 

 —